|Table of Contents|

Efficacy of interferon-α combined with arsenite in the treatment of JAK2V617F mutation-positive polycythemia vera and essential thrombocythemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 06
Page:
1072-1075
Research Field:
Publishing date:

Info

Title:
Efficacy of interferon-α combined with arsenite in the treatment of JAK2V617F mutation-positive polycythemia vera and essential thrombocythemia
Author(s):
LEI Linzi; WANG Yaomei; LIU Yuzhang; LIU Lina; FANG Baijun
Department of Hematology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Henan Zhengzhou 450008,China.
Keywords:
polycythemia vera; essential thrombocythemia; interferon-α; arsenite; clinical efficacy
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2022.06.025
Abstract:
Objective:To observe the efficacy and safety of interferon-α (IFN-α) combined with arsenite in the treatment of JAK2V617F mutation-positive patients with polycythemia vera (PV) and essential thrombocythemia (ET).Methods:The clinical data of 44 patients with PV and ET in department of hematology in our hospital from December 2015 to January 2021 were retrospectively analyzed,and the efficacy and adverse reactions of IFN-α combined with arsenite (observation group) and IFN-α alone (control group) were compared.Results:The hematological overall response rate (ORR) of observation group was 88.5%,which was higher than that of control group.By the end of follow-up,the ORR of hematology and molecular biology remission in observation group was higher than that of control group.And there were no serious adverse reactions during the treatment in observation group.Conclusion:Arsenite can accelerate and enhance the anti-tumor effect of IFN-α,and the combination of the two therapies can improve the clinical remission rate and duration of efficacy of JAK2V617F mutation-positive PV and ET,with high safety.

References:

[1] ARBER DA,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia［J］.Blood,2016,127(20):2391-2405.
[2] AUSTIN RJ,STRAUBE J,BRUEDIGAM C,et al.Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations［J］.Leukemia,2020,34(4):1075-1089.
[3] DAGHER T,MASLAH N,EDMOND V,et al.JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML［J］.J Exp Med,2021,218(2):e20201268.
[4] TEFFERI A,RUMI E,FINAZZI G,et al.Survival and prognosis among 1545 patients with contemporary polycythemia vera:an international study［J］.Leukemia,2013,27(9):1874-1881.
[5] PASSAMONTI F,THIELE J,GIRODON F,et al.A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis:a study by the International Working Group on Myelofibrosis Research and Treatment［J］.Blood,2012,120(6):1197-1201.
[6] BAROSI G,MESA R,FINAZZI G,et al.Revised response criteria for polycythemia vera and essential thrombocythemia:an ELN and IWG-MRT consensus project［J］.Blood,2013,121(23):4778-4781.
[7] VAINCHENKER W,KRALOVICS R.Genetic basis and molecularpathophysiology of classical myeloproliferative neoplasms［J］.Blood,2017,129(6):667-679.
[8] SPIVAK JL.How I treat polycythemia vera［J］.Blood,2019,134(4):341-352.
[9] VERGER E,SORET-DULPHY J,MASLAH N,et al.Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo［J］.Blood Cancer J,2018,8(10):94.
[10] KILADJIAN JJ,GIRAUDIER S,CASSINAT B.Interferon-alpha for the therapy of myeloproliferative neoplasms:targeting the malignant clone［J］.Leukemia,2016,30(4):776-781.
[11] WALTER D,LIER A,GEISELHART A,et al.Exit from dormancy provokes DNA-damage-induced attrition inhaematopoietic stem cells［J］.Nature,2015,520:549-552.
[12] ZHAO J,SONG Y,LIU L,et al.Effect of arsenic trioxide on the Tregs ratio and the levels of IFN-γ,IL-4,IL-17 and TGF-β1 in the peripheral blood of severe aplastic anemia patients［J］.Medicine,2020,99(26):e20630.
[13] EL EIT R,ITANI AR,NASSAR F,et al.Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors［J］.Cancer,2019,125(16):2818-2828.
[14] LALLEMAND-BREITENBACH V,DE TH H.PML nuclear bodies:from architecture to function［J］.Curr Opin Cell Biol,2018,52:154-161.
[15] NIWA-KAWAKITA M,FERHI O,SOILIHI H,et al.PML is a ROS sensor activating p53 upon oxidative stress［J］.J Exp Med,2017,214(11):3197-3206.
[16] VERNIER M,FERBEYRE G.Complete senescence:RB and PML share the task［J］.Cell Cycle,2014,13(5):696.
[17] BYWATER M,LANE SW.A knockout combination for MPN stem cells［J］.J Exp Med,2021,218(2):e20201884.

Memo

Memo:
National Natural Science Foundation of China(No.81900108）；国家自然科学基金资助项目(编号：81900108);中原英才计划基金资助项目(编号：214200510023)
Last Update: 1900-01-01